eXoZymes (NASDAQ:EXOZ – Get Free Report) and Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.
Earnings and Valuation
This table compares eXoZymes and Allogene Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| eXoZymes | $70,000.00 | 554.41 | -$9.16 million | ($1.19) | -3.51 |
| Allogene Therapeutics | $20,000.00 | 23,061.46 | -$190.89 million | ($0.67) | -1.99 |
eXoZymes has higher revenue and earnings than Allogene Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for eXoZymes and Allogene Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| eXoZymes | 1 | 1 | 0 | 0 | 1.50 |
| Allogene Therapeutics | 1 | 3 | 8 | 2 | 2.79 |
Allogene Therapeutics has a consensus target price of $8.30, suggesting a potential upside of 521.72%. Given Allogene Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than eXoZymes.
Insider and Institutional Ownership
83.6% of Allogene Therapeutics shares are owned by institutional investors. 58.0% of eXoZymes shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
eXoZymes has a beta of 3.19, suggesting that its stock price is 219% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.
Profitability
This table compares eXoZymes and Allogene Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| eXoZymes | N/A | -292.15% | -158.66% |
| Allogene Therapeutics | N/A | -50.04% | -36.74% |
Summary
Allogene Therapeutics beats eXoZymes on 10 of the 14 factors compared between the two stocks.
About eXoZymes
eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
About Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Receive News & Ratings for eXoZymes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eXoZymes and related companies with MarketBeat.com's FREE daily email newsletter.
